The 2015 ACR guideline for RA treatment specifies that TNF inhibitors should be used before JAK inhibitors (jakinibs) for the treatment of RA when a patient fails to have an adequate response to conventional DMARDs. However, emerging data indicate that jakinibs may be even more effective than TNF inhibitors. Is it time to revisit this recommendation? That’s the question for the 2020 Great Debate: Nov. 6, 10 a.m. EST.
You are here: / / The Great Debate at ACR Convergence 2020: Should Jakinibs Be Used Before Biologics for RA?